about
Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular CarcinomaMiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor MetabolismEndoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells.Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma CellsLncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells.Granulin-epithelin precursor interacts with 78-kDa glucose-regulated protein in hepatocellular carcinomaInduction of apoptosis and proliferation inhibition of hepatocellular carcinoma by 6-chloro-2-methoxy-N-(phenylmethyl)-9-acridinamine (BA): in vitro and vivo studies.Antiproliferative and apoptotic effects of β-elemene on human hepatoma HepG2 cellsEnhanced antitumor effects of adenoviral-mediated siRNA against GRP78 gene on adenosine-induced apoptosis in human hepatoma HepG2 cells.Knockdown of autophagy-related gene LC3 enhances the sensitivity of HepG2 cells to epirubicinImmunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.Sgo1 is a potential therapeutic target for hepatocellular carcinoma.Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic reviewTherapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics.Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice.Reversibility of regorafenib effects in hepatocellular carcinoma cells.Nexavar(®)-related adverse reactions: Calabrian (Italy) experience for sorafenib exposition in 2012.Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases - should we think about revising the current treatment guidelines in selChemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway.Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells.Glypican-3 antibodies: a new therapeutic target for liver cancer.Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.Long-term Branched Chain Amino Acid Supplementation Ameliorates Diethylnitrosamine-induced Liver Glutathione S-transferase-p Positivity in Zucker Fatty Rats.Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells.Synergistic Anticancer Activities of Natural Substances in Human Hepatocellular Carcinoma.Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt.An Unusual Presentation of Advanced Intrahepatic Cholangiocarcinoma: When Biopsy Results Fail.CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy AgentsMelatonin Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy Through Long Non-Coding RNA RAD51-AS1-Mediated Suppression of DNA Repair
P2860
Q26782003-B8495F37-4A81-4521-8407-7949B1A6F085Q28551765-848C669D-9937-41C7-947D-1BE1EA85EADAQ30455973-53E22475-80BB-4C85-A723-1363CB4594EEQ32177411-EEF5A178-493F-4DC6-8EF4-A4CF7F1F9CF0Q33707998-52245DC6-CECB-4020-8CD1-5442B2B4ED01Q33785050-63A70D31-6556-448D-8F8B-4CEF36F4E317Q33868747-4712709D-47FA-407B-8E2C-37C7AD52FAE8Q34621667-97016FB4-D4FF-4E62-9D3E-B2FCC0D85951Q35084023-85E17951-113C-4F8C-B459-E3DBC0020A42Q35159686-7606B2FA-5032-4E73-B9EB-FFBB2194C887Q35170403-47DA9B90-5EAC-4A8F-B845-22F9D85CAEF0Q35273343-271C3BAD-97A2-411A-9B31-400ECC229E8BQ35298023-359AF92E-327E-4F86-8806-6685BC35D532Q36712597-CCBC16F3-E5A9-4E1C-AC86-2C5F49F49175Q36839348-C90388EE-2407-44ED-AB1E-145CACC4C308Q37301702-03FBF290-24A1-4312-BAFA-6B26416C51F5Q37332505-22AF20D1-A87E-4BBF-9A83-815EB9E34693Q37369681-BD34766C-D53B-4720-A846-947541966213Q37376515-2AAF0F68-2994-4C93-AFD1-FB96C5106ED0Q37412481-FF805FCC-CA54-450C-8381-464B6E9A38BEQ37520477-028FFE4F-EAFB-4C61-8FB8-0B0DD396EAFDQ37540019-47A36A48-64D1-4408-9547-7CF40E952995Q37625736-057AC17C-6B34-45D3-BC94-0B2910B449E7Q37685728-8D4A0672-F1B5-4AF4-9A68-778514B45822Q37743524-C2DA4F1C-AA7C-4CAA-818E-3974F4772F99Q38923517-4B198516-B1C5-480E-890B-D3929F40CBDDQ39030337-753B3846-9A2C-4864-8799-2ACB19099DBCQ41138780-F41CADEB-8FCF-4DBA-BA43-A1A824F36EAFQ41258322-AF6F4A46-AD44-46F6-9337-D382A27B2C53Q41874076-97420002-2CCA-4D78-B368-A3DEAEDB0125Q42343450-BDC64D8D-E4AB-4D5A-B006-2ED967F21997Q47387460-404B02A3-3C9E-475E-A087-7D2957E7706CQ47556044-C2A27C31-016B-42AA-8FC6-09DACE46070DQ58746251-34DD6334-29C7-4C83-A185-86FF6857F6CAQ58753461-8142E80E-B961-4271-8968-8307243A1BCC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Improved chemotherapy for hepatocellular carcinoma.
@en
type
label
Improved chemotherapy for hepatocellular carcinoma.
@en
prefLabel
Improved chemotherapy for hepatocellular carcinoma.
@en
P2093
P1433
P1476
Improved chemotherapy for hepatocellular carcinoma
@en
P2093
P304
P407
P577
2012-04-01T00:00:00Z